Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

RET receptor tyrosine kinase is activated in various cancers (lung, thyroid, colon and pancreatic, among others) through oncogenic fusions or gain-of-function single-nucleotide variants. Small-molecule RET kinase inhibitors became standard-of-care therapy for advanced malignancies driven by RET. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, Somwar, Romel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518257/
https://www.ncbi.nlm.nih.gov/pubmed/37743366
http://dx.doi.org/10.1038/s43018-023-00630-y

Ejemplares similares

Ejemplares similares